(NASDAQ: ARWR) Arrowhead Pharmaceuticals's forecast annual revenue growth rate of 398.25% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.48%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.37%.
Arrowhead Pharmaceuticals's revenue in 2025 is $2,500,000.On average, 7 Wall Street analysts forecast ARWR's revenue for 2025 to be $45,424,700,820, with the lowest ARWR revenue forecast at $315,245,278, and the highest ARWR revenue forecast at $114,307,937,622. On average, 7 Wall Street analysts forecast ARWR's revenue for 2026 to be $32,060,444,722, with the lowest ARWR revenue forecast at $12,824,177,889, and the highest ARWR revenue forecast at $71,333,701,393.
In 2027, ARWR is forecast to generate $44,677,947,807 in revenue, with the lowest revenue forecast at $17,489,807,996 and the highest revenue forecast at $67,727,295,418.